Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD-L1, PD-L2 peptides with Montanide ISA51 · 1 trial · 1 indication
Progressive disease (PD), stable disease (SD), partial response (PR), complete response (CR) calculated on basis of changes in circulating lymphocytes and lymphnode/spleen/liver size according to criteria from the international working group on CLL (IW-CLL).
| Arm | Type | Description |
|---|---|---|
| Vaccination | EXPERIMENTAL | Untreated CLL patients with unmutated IgHV gene with a cut of at maximum of 2 % mutations. According to guidelines from the European Research Initiative on CLL (ERIC). |
| Name | Type | Description |
|---|---|---|
| PD-L1, PD-L2 peptides with Montanide ISA51 | COMBINATION_PRODUCT | PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide. |
Inclusion Criteria: * CLL according to national guidelines (Lymphoma.dk). * Unmutated IGHV gene according to ERIC recommendations.(25) * No prior CLL directed treatment * Age ≥ 18 * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 * No life-threatening conditions * Adequate bo...
PD-L1, PD-L2 peptides with Montanide ISA51 is an investigational peptide vaccine being studied for high risk non-muscle invasive bladder urothelial carcinoma and chronic lymphocytic leukemia. It is also known as PD-L1/IDO Peptide Vaccine and is developed by IO Biotech, Inc. (IOBT).
PD-L1, PD-L2 peptides with Montanide ISA51 targets PD-L1 and PD-L2, which are immune checkpoint proteins. By vaccinating against these targets, the therapy aims to stimulate an immune response against cancer cells that express these proteins.
PD-L1, PD-L2 peptides with Montanide ISA51 is developed by IO Biotech, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker IOBT. The company is conducting clinical trials to evaluate the vaccine in oncology indications.
PD-L1, PD-L2 peptides with Montanide ISA51 is in Phase 2 clinical development. It is investigational and not yet approved by regulatory authorities. The vaccine is being studied in patients with high risk non-muscle invasive bladder cancer and chronic lymphocytic leukemia.
PD-L1, PD-L2 peptides with Montanide ISA51 has been studied in two clinical trials. NCT03939234, a completed Phase 2 trial in chronic lymphocytic leukemia, enrolled 19 patients in Denmark. NCT05843448, a recruiting Phase 1 trial, is evaluating the vaccine with pembrolizumab in non-muscle invasive bladder cancer in the United States.
Yes, PD-L1, PD-L2 peptides with Montanide ISA51 is also known as PD-L1/IDO Peptide Vaccine. The alternative name reflects the vaccine's inclusion of IDO peptides, which are being studied for their immune-modulatory effects in cancer treatment.